Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 08, 2026 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14

NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need,...
April 08, 2026 08:00 ET | Source: electroCore, Inc.

electroCore to Participate in the 25th Annual Needham Virtual Healthcare Conference

ROCKAWAY, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate...
April 08, 2026 08:00 ET | Source: Biora Therapeutics

Biora Therapeutics Advances BioJet™ Swallowable Autoinjector

Company reports >25% oral bioavailability in swine and non-human primatesProgressing multiple collaborations toward partnerships SAN DIEGO, April 08, 2026 (GLOBE NEWSWIRE) -- Biora Therapeutics,...
April 08, 2026 07:30 ET | Source: Tris Pharma, Inc.

Tris Pharma to Showcase Encore Phase 3 Data Supporting Continued Progress in Acute Pain Treatment at ASRA 2026 Meeting in Phoenix

– Encore data to be presented demonstrating that cebranopadol displays significant and sustained pain reduction with a distinguished safety profile following abdominoplasty and bunionectomy – –...
April 08, 2026 07:00 ET | Source: Climb Bio, Inc.

Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026

WELLESLEY HILLS, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today...
April 08, 2026 07:00 ET | Source: BioXcel Therapeutics

BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions

DoW-funded Phase 2a trial led by University of North Carolina at Chapel Hill (UNC) Institute for Trauma Recovery Positive outcomes from trial can potentially impact Veteran Affairs/Department of War...
April 08, 2026 07:00 ET | Source: TScan Therapeutics, Inc.

TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

WALTHAM, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T...
April 08, 2026 03:00 ET | Source: Aravax

Aravax Strengthens Board with Appointments of Carsten Hellmann and Andrew Oxtoby

MELBOURNE, Australia and OXFORD, United Kingdom, April 08, 2026 (GLOBE NEWSWIRE) -- Aravax, a clinical-stage biotechnology company developing next-generation, disease-modifying immunotherapies for...
April 08, 2026 02:17 ET | Source: Novonesis (Novozymes A/S)

Novonesis expands global footprint with acquisition of production facility in Southeast Asia

Novonesis expands global footprint with acquisition of production facility in Southeast Asia Investment of around USD 50 million strengthens fermentation capabilities and supports the company’s...
April 07, 2026 16:50 ET | Source: NovaBridge Biosciences

NovaBridge Reports Full Year 2025 Financial Results and Provides Business Update

Successful transformation to global biotech platform with two mid-stage potential best-in-class/first-in-class programs, givastomig and VIS-101, with compelling proof-of-concept dataGivastomig, a...